Zylox-Tonbridge Medical Technology Co (FRA:818) Debt-to-Equity : 0.02 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Zylox-Tonbridge Medical Technology Co Debt-to-Equity?

Zylox-Tonbridge Medical Technology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €6.94 Mil. Zylox-Tonbridge Medical Technology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.24 Mil. Zylox-Tonbridge Medical Technology Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €391.37 Mil. Zylox-Tonbridge Medical Technology Co's debt to equity for the quarter that ended in Dec. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Zylox-Tonbridge Medical Technology Co's Debt-to-Equity or its related term are showing as below:

FRA:818' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.14
Current: 0.02

During the past 5 years, the highest Debt-to-Equity Ratio of Zylox-Tonbridge Medical Technology Co was 0.14. The lowest was 0.00. And the median was 0.02.

FRA:818's Debt-to-Equity is ranked better than
91.98% of 698 companies
in the Medical Devices & Instruments industry
Industry Median: 0.215 vs FRA:818: 0.02

Zylox-Tonbridge Medical Technology Co Debt-to-Equity Historical Data

The historical data trend for Zylox-Tonbridge Medical Technology Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zylox-Tonbridge Medical Technology Co Debt-to-Equity Chart

Zylox-Tonbridge Medical Technology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.14

0.08

0.01

0.02

Zylox-Tonbridge Medical Technology Co Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial				-	-	0.01	0.01	0.02

Competitive Comparison of Zylox-Tonbridge Medical Technology Co's Debt-to-Equity

For the Medical Devices subindustry, Zylox-Tonbridge Medical Technology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zylox-Tonbridge Medical Technology Co's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zylox-Tonbridge Medical Technology Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Zylox-Tonbridge Medical Technology Co's Debt-to-Equity falls into.

Zylox-Tonbridge Medical Technology Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Zylox-Tonbridge Medical Technology Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.937	+	0.239)	/	391.369
	=	0.02

Zylox-Tonbridge Medical Technology Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.937	+	0.239)	/	391.369
	=	0.02

Zylox-Tonbridge Medical Technology Co (FRA:818) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Zylox-Tonbridge Medical Technology Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Zylox-Tonbridge Medical Technology Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Zylox-Tonbridge Medical Technology Co (FRA:818) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zylox-Tonbridge Medical Technology Co Ltd (FRA:818) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

02190:Hong Kong

Address

No. 18 Keji Avenue, Yuhang Street, 1st & 2nd Floors, Building 1, Yuhang District, Zhejiang Province, Hangzhou, CHN

Website

https://www.zyloxtb.com

Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries.

Zylox-Tonbridge Medical Technology Co (FRA:818) Headlines

No Headlines